Press Releases

Newsroom Press releases TN in the News Conferences Executive team

Oct 29, 2024

Terumo Neuro and Tulane University School of Medicine’s Dr. Kendrick Johnson Release Educational Video Highlighting the Importance of Stroke Awareness and Equitable Healthcare in Honor of World Stroke Day 2024

In honor of World Stroke Day on October 29, 2024, Terumo Neuro has partnered with Tulane University School of Medicine and Dr. Kendrick Johnson, Assistant Professor of Neurosurgery at Tulane University School of Medicine, to release a compelling educational video focused on raising awareness about stroke education and the critical need for equitable healthcare access.

Sep 12, 2024

MicroVention Rebrands to Terumo Neuro - Reflects Expanded Focus and Strategic Growth

MicroVention, Inc., a global leader in neurovascular innovation and a wholly owned subsidiary of Terumo Corporation, today announced its official rebranding to Terumo Neuro, effective immediately. This name change signifies a new chapter in the company’s evolution while maintaining its unwavering commitment to the creation and commercialization of groundbreaking innovations in neurovascular care.

Jul 23, 2024

MicroVention Announces Release of CLinical EValuation of WEB™ 17 Device in Intracranial Aneurysms (CLEVER): One Year Effectiveness Results for Ruptured and Unruptured Aneurysms

MicroVention, Inc., a global neurovascular company and wholly owned subsidiary of Terumo Corporation, today announced the recently published results of the CLinical EValuation of WEB 17 Device in Intracranial Aneurysms (CLEVER): One Year Effectiveness Results for Ruptured and Unruptured Aneurysms.

Jul 16, 2024

MicroVention Announces Settlement Against Former Employees for Trade Secret Misappropriation and Breach of Contract Among Other Claims

MicroVention announced today that the United States District Court for the Central District of California has issued an injunction permanently enjoining defendants David Ferrera, Nguyen (“Jake”) Le and Michelle Tran, former employees of MicroVention (“defendants”), from using, disclosing, or possessing any MicroVention trade secret information or confidential information.

Jul 9, 2024

MicroVention Announces Clinical Publication of SOFAST: SOFIA™ Aspiration System as First Line Technique in Treating Acute Ischemic Stroke

SOFIA™ Aspiration Catheters Have Continued to Set the Standard for Over 10 Years with Renowned Trackability, Speed and Proven Clinical Performance

Jun 26, 2024

MicroVention Announces the Next Evolution in Stent Innovation: MicroVention’s LVIS™ EVO™ Intraluminal Support Device Now Available in the United States

The LVIS™ EVO™ Intraluminal Support Device is now commercially available in the United States for the treatment of wide neck intracranial aneurysms. LVIS EVO has been available in Europe since 2019 and over 12,000 units have been sold. LVIS EVO is the first fully visible coil-assist-intracranial stent available in the US Market.

Nov 16, 2023

MicroVention Celebrates 10-Year Anniversary and Legacy of SOFIA™ Aspiration Catheters; More than 500,000 Procedures Performed Worldwide Across 170 Countries

SOFIA™ Set the Standard 10 Years Ago with Renowned Trackability, Speed and Proven Clinical Performance.

Sep 21, 2023

MicroVention Enters Transradial Access Therapy; Receives FDA Clearance of SOFIA™ EX 5F 115cm Intracranial Support Catheter

MicroVention, Inc., a global neurovascular company and wholly owned subsidiary of Terumo Corporation, today announced that the SOFIA™ EX 5F 115 cm Intracranial Support Catheter (Soft TOrqueable catheter For Intracranial Access) has received FDA 510(k) clearance on September 15, 2023, for transradial access in addition to transfemoral access.

Jul 31, 2023

MicroVention Celebrates One-Year Anniversary of FRED™ X Flow Diverter with Over 1,000 Patients Treated Across the U.S.

The FRED X Flow Diverter is the Next Generation in Flow Diversion Technology

Jul 31, 2023

MicroVention Announces 5-Year Clinical Trial Data and Size Additions for its WEB Aneurysm Embolization System; WEB is Most Well-Studied Intrasaccular Device Available Today

MicroVention’s WEB System is the World Leader and Only PMA-Approved Intrasaccular Flow Disruptor; Advances Treatment of Wide-Neck Bifurcation Aneurysms with ONE Device

Jun 27, 2023

MicroVention Reshapes Stroke Therapy with the Introduction of the ERIC™ Retrieval Device; ERIC Delivers Thrombus Control, Procedure Efficiency and Versatility When Every Second Counts

MicroVention Now Offers a Fully Integrated, Comprehensive Stroke Portfolio, Delivering Breakthrough Innovation from Access to Revascularization

Apr 11, 2023

Costa Rica's President Rodrigo Chaves Robles Recognizes MicroVention's Achievements with its Door To The Future Program and Signs National Employment Program Decree at MicroVention

Aliso Viejo, California andAlajuela, Costa Rica, April 11, 2023 – MicroVention, Inc., a global neurovascular company and wholly owned subsidiary of Terumo Corporation, today hosted the Republic of Costa Rica’s President Rodrigo Chaves Robles and other government officials and dignitaries at its Costa Rica facility in Alajuela.

Sep 29, 2022

MicroVention Celebrates 25 Years in Neuroendovascular Technologies that Improve Patient Lives

MicroVention, Inc., a global neurovascular company and a wholly owned subsidiary of Terumo Corporation, celebrates its 25-year anniversary on September 29, 2022. Founded in 1997 by a handful of Associates in Southern California, MicroVention is now a worldwide community with over 3,000 Associates and distributors worldwide, with offices across the United States, Europe, Asia, and Costa Rica.

Aug 22, 2022

MicroVention Earns 2022 Great Place to Work Certification™

The prestigious award is based entirely on what current employees say about their experience working at MicroVention. This year, 80% of employees said it’s a great place to work – 21 points higher than the average U.S. company.

Apr 20, 2022

MicroVention Announces First Patient Enrolled in the STRAIT Study with the New BOBBY™ Balloon Guide Catheter

MicroVention, Inc., a wholly owned subsidiary of Terumo Corporation, announced the successful completion of its first enrollment in a multi-center, prospective EU observational study called STRAIT, to evaluate the Safety and Performance of the BOBBY Balloon Guide Catheter for Endovascular Treatment of Acute Ischemic Stroke.

Feb 22, 2022

MicroVention Announces First U.S. Patient Treated with FRED™ X™ Flow Diverter Featuring X Technology

MicroVention, Inc., a subsidiary of Terumo and a global neurovascular company, announced the first U.S. clinical case of its next generation Flow Diverter, the FRED X device, at Thomas Jefferson University Hospital located in Philadelphia.

Jan 12, 2021

Lower-Profile WEB Intrasaccular Aneurysm Treatment Device Receives FDA Approval

The WEB™ Aneurysm Embolization System expands with a lower profile delivery system and new size configurations.

Dec 23, 2020

MicroVention, Inc. Files Trade Secret Lawsuit Against Balt USA, LLC

MicroVention, Inc., a U.S. based subsidiary of Terumo and leading global neurovascular company, announced today the filing of a second lawsuit against Balt USA, LLC and four former employees for trade secret misappropriation.

Sep 22, 2020

MicroVention-Terumo Announces New Leadership

The Company Appoints New President and CEO

Apr 22, 2020

Terumo Donates USD 2.4 Million in Cash and Products to Support COVID-19 Pandemic Relief Efforts Worldwide

Contributions include USD 1 million to the COVID-19 Solidarity Response Fund for WHO

Mar 27, 2020

MicroVention's Response to COVID-19

MicroVention has been closely following the daily developments and guidelines surrounding COVID-19, and our commitment remains true as we adjust to the current circumstances that all of us are facing during this challenging time.

Mar 13, 2020

MicroVention Expands Worldwide Innovation Center

Two years after MicroVention, Inc. relocated their Worldwide Innovation Center to 35 Enterprise, the neurovascular company is expanding within the Summit Office Campus to accommodate for their rapid growth.

Jan 8, 2020

MicroVention Announces FDA Premarket Approval of a New Flow Diverter for the Treatment of Brain Aneurysms

MicroVention, Inc., a U.S. based subsidiary of Terumo and a global neurovascular company announced the FDA Premarket Approval (PMA) for the FRED® (Flow Re-Direction Endoluminal Device) device for the treatment of brain aneurysms.

Oct 18, 2019

Treating brain aneurysms before they rupture: How Indiana doctors are using a new aneurysm treatment

The Woven EndoBridge (WEB) Aneurysm Embolization System, approved for use in January, has made its way to Indiana.

Apr 24, 2019

MicroVention Announces Positive Safety and Effectiveness Results in WEB-IT Pivotal Trial Published in Journal of Neurointerventional Surgery

The WEB-IT pivotal trial highlights positive clinical outcomes with the WEB® Aneurysm Embolization System, the only intrasaccular flow disruptor approved in the United States.

Jan 7, 2019

Novel Intrasaccular Aneurysm Treatment Device Receives FDA PMA Approval

The WEB® Aneurysm Embolization System is the first intrasaccular flow disruptor PMA approved for the embolization of wide neck bifurcation aneurysms

Jun 12, 2018

MicroVention Announces FDA Clearance for Thrombectomy Device

Microvention Announces FDA Clearance for Thrombectomy Device. SOFIA® Catheter; A New Device for the Revascularization of Patients with Acute Ischemic Stroke

May 31, 2018

MicroVention® Announces FDA Approval For Neuro Stent Device

The LVIS® and LVIS® Jr. stents are the first stents PMA approved for stent-assisted coil embolization

Sep 26, 2017

MicroVention Celebrates Grand Opening of New Worldwide Innovation Center in Aliso Viejo, California

Microvention Celebrates Grand Opening of New Worldwide Innovation Center in Aliso Viejo, California and also Celebrates 20th Anniversary in New 205,000 Square-Foot Facility

Jun 20, 2017

Orange Country Business Journal Article On MicroVention

Maker of Tiny Devices Goes Big With New Base

Mar 7, 2017

MicroVention and Terumo Corporation Announce Data from Multicenter GREAT Study

Randomized, Controlled, 500-Patient Trial Showed Patients Treated by Hydrogel Coils Less Likely to Have Adverse Outcomes than those Treated by Standard Bare Platinum Coils; Data Presented at International Stroke Conference 2017

Jul 14, 2016

Terumo Corporation Completes Acquisition of Sequent Medical

Unique Aneurysm Embolization Device Complements MicroVention’s Neurovascular Product Portfolio

Jun 15, 2016

Terumo Corporation Acquires Sequent Medical

MicroVention Gains Developer of New Aneurysm Embolization Device

Jun 14, 2016

Terumo Acquires Sequent Medical, U.S.-based Developer of New Aneurysm Embolization Device

Sep 20, 2015

MicroVention Goes Back to Its Roots

Back to Its Roots: Neurovascular company to come home to much bigger house

Jun 1, 2015

MicroVention to Locate Its New 205,000 Square-Foot Worldwide Headquarters At Summit Office Campus in Aliso Viejo

Groundbreaking Ceremony to be Held June 4, 2015; Occupancy Expected First Half of 2017

Jul 22, 2013

FRED First U.S. Case

MicroVention Announces First Trial Enrollment In Their U.S. Clinical Trial of Its New Dual-Layer Stent For Cerebral Aneurysm Flow Diversion

Mar 6, 2013

Microvention Costa Rica Plant Opening

Microvention's New Manufacturing Plant Facility In Costa Rica Celebrates Grand Opening With Inaugural Plant Ceremony

Jul 2, 2012

HEAT Trial

MicroVention Announces First Patient Enrollment In Clinical Trial To Compare Coiling Technologies For Treating Brain Aneurysms

Aug 3, 2010

Final Data In International Trial Supports Safety and Effectiveness of MicroVention-Terumo’s HydroCoil® Embolic System for Treatment of Cerebral Aneurysms

Statistically Significant Angiographic Results Show the HydroCoil Embolization System Reduces Major Recurrence Rates in 500-Patient, International Clinical Trial